Market Access After COVID-19: Sector Goodwill Or Hard Crackdown?
Executive Summary
The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.
You may also be interested in...
EQRx Aims To Dent Saturated, But Still Expensive, PD-1 Market
EQRx is one of several Western companies that have been looking to China for new PD-1 inhibitors at a lower cost.
In US Drug Pricing Debate, ICER’s Voice Gets Louder
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.
Pandemic Spotlights Tensions Between Profit And Philanthropy
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.